Homepage (original) (raw)
Bexmarilimab is a first-in-class, humanized monoclonal antibody that binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e., it helps cancer to evade the immune system), and a novel immune checkpoint target for drug development.
By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.